down arrow

Baudax Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US07160F4046
USD
0.00
0.00 (0.00%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

7

Shareholding (Dec 2023)

FII

0.06%

Held by 5 FIIs

DII

99.72%

Held by 0 DIIs

Promoter

0.00%

How big is Baudax Bio, Inc.?

22-Jun-2025

As of September 2023, Baudax Bio, Inc. has an unavailable market capitalization, with net sales of $0.31 million and a consolidated net profit of -$25.83 million over the last four quarters. As of December 2022, shareholder's funds were -$24.24 million, and total assets were $10.03 million.

Market Cap: As of September 2023, Baudax Bio, Inc. has a market capitalization value that is not available. Therefore, it cannot be classified into any market cap type.<BR><BR>Recent Quarterly Performance: As of September 2023, the sum of net sales for the latest four quarters is 0.31 million. The sum of consolidated net profit for the same period is -25.83 million.<BR><BR>Balance Sheet Snapshot: As of December 2022, the shareholder's funds amount to -24.24 million, and the total assets are 10.03 million.

Read More

Is Baudax Bio, Inc. overvalued or undervalued?

25-Jun-2025

As of May 12, 2023, Baudax Bio, Inc. is considered overvalued and has moved from a risky valuation grade to "does not qualify," with significant financial distress indicated by a P/E ratio of 0.00 and a negative return of -100% over the past year compared to the S&P 500's positive return of 10.26%.

As of 12 May 2023, Baudax Bio, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its financial metrics and peer comparisons. Notably, Baudax has a P/E ratio of 0.00, an EV to EBIT of -0.65, and an EV to EBITDA of -0.66, all of which indicate significant financial distress.<BR><BR>In comparison to its peers, Baudax Bio, Inc. stands out negatively against companies such as ABVC BioPharma, Inc., which has a P/E ratio of -15.31, and Plus Therapeutics, Inc., with a P/E ratio of -0.43. The substantial negative return over the past year of -100% further emphasizes the company's struggles, especially when juxtaposed with the S&P 500's positive return of 10.26% during the same period. Overall, Baudax Bio, Inc. is deemed overvalued based on its current financial standing and performance relative to its peers.

Read More

Is Baudax Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of June 13, 2025, Baudax Bio, Inc. shows a mildly bearish trend, with mixed signals from indicators like the MACD and RSI, and a significant decline over the past three to five years compared to the S&P 500.

As of 13 June 2025, the technical trend for Baudax Bio, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the RSI shows a bullish stance on the weekly but is bearish on the monthly, suggesting mixed signals. The daily moving averages are mildly bearish, reinforcing the overall bearish trend. The Bollinger Bands indicate a mildly bearish stance on the weekly and sideways on the monthly. <BR><BR>In terms of performance, the company has seen a significant decline over the past three years and five years, with returns of -100%, compared to the S&P 500's gains of 70.41% and 96.61%, respectively. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the RSI and Bollinger Bands.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.39

stock-summary
Return on Equity

368.47%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2023)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-100.0%
0%
-100.0%
1 Year
0%
0%
0.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Baudax Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Baudax Bio, Inc. technically bullish or bearish?

As of 13 June 2025, the technical trend for Baudax Bio, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the RSI shows a bullish stance on the weekly but is bearish on the monthly, suggesting mixed signals. The daily moving averages are mildly bearish, reinforcing the overall bearish trend. The Bollinger Bands indicate a mildly bearish stance on the weekly and sideways on the monthly. In terms of performance, the company has seen a significant decline over the past three years and five years, with returns of -100%, compared to the S&P 500's gains of 70.41% and 96.61%, respectively. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the RSI and Bollinger Bands....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.98%
EBIT Growth (5y)
12.56%
EBIT to Interest (avg)
-24.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.39
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.75%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-0.65
EV to EBITDA
-0.66
EV to Capital Employed
3.56
EV to Sales
14.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-547.36%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (0.22%)

Foreign Institutions

Held by 5 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 73.97% vs 1.35% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-4.00",
          "chgp": "-32.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.80",
          "val2": "-3.00",
          "chgp": "226.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.90",
          "val2": "-7.30",
          "chgp": "73.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 18.18% vs 120.00% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -196.97% vs 73.98% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "1.10",
          "chgp": "18.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.60",
          "val2": "-49.60",
          "chgp": "32.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.10",
          "val2": "33.40",
          "chgp": "-163.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.80",
          "val2": "-19.80",
          "chgp": "-196.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-28,166.30%",
          "val2": "-48,496.30%",
          "chgp": "2,033.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQstock-summary
Sep'23
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.30
-4.00
-32.50%
Interest
0.10
0.30
-66.67%
Exceptional Items
3.80
-3.00
226.67%
Consolidate Net Profit
-1.90
-7.30
73.97%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is 73.97% vs 1.35% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
1.30
1.10
18.18%
Operating Profit (PBDIT) excl Other Income
-33.60
-49.60
32.26%
Interest
0.00
2.30
-100.00%
Exceptional Items
-21.10
33.40
-163.17%
Consolidate Net Profit
-58.80
-19.80
-196.97%
Operating Profit Margin (Excl OI)
-28,166.30%
-48,496.30%
2,033.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 18.18% vs 120.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -196.97% vs 73.98% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Baudax Bio, Inc. stock-summary
stock-summary
Baudax Bio, Inc.
Pharmaceuticals & Biotechnology
Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.
Company Coordinates stock-summary
Company Details
490 Lapp Rd , MALVERN PA : 19355-1212
stock-summary
Tel:
stock-summary
https://www.baudaxbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."